To summarize, on one hand the modest upwards trajectory of the obese and diabetic population provides a fertile ground for Pharma companies to sell more for the years to come, however, downside risks remain, including: pricing, compounders and overall competition, which will make it hard for companies like Novo and Lilly to maintain their growth
Available from: Wharton S, Lau DCW, Vallis M, et al
I am pleased that the POM Wonderful case has been brought to a successful conclusion, Ramirez said
So, Should You Pick NAC or Glutathione
GLP-1 stands for glucagon-like peptide-1, a gut hormone pathway linked with appetite and insulin response
The focus isnt rapid weight loss